Immunome
IMNM
29 hedge funds and large institutions have $41.1M invested in Immunome in 2021 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 8 increasing their positions, 7 reducing their positions, and 13 closing their positions.
14% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 7
2.3% more ownership
Funds ownership: 17.91% → 20.21% (+2.3%)
6% less funds holding
Funds holding: 31 → 29 (-2)
15% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 13
36% less capital invested
Capital invested by funds: $64.6M → $41.1M (-$23.5M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $5K
Top Buyers
| 1 |
PCM
Prentice Capital Management
Greenwich,
Connecticut
|
+$4.09M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.27M |
| 3 |
AGM
Alpine Global Management
New York
|
+$1.3M |
| 4 |
RI
Ridgewood Investments
Springfield,
New Jersey
|
+$1.28M |
| 5 |
Millennium Management
New York
|
+$810K |
Top Sellers
| 1 |
BlackRock
New York
|
-$1.99M |
| 2 |
State Street
Boston,
Massachusetts
|
-$1.1M |
| 3 |
Northern Trust
Chicago,
Illinois
|
-$918K |
| 4 |
BIM
Baldwin Investment Management
West Conshohocken,
Pennsylvania
|
-$860K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$217K |
IMNM Hedge Fund Activity: Q2 2021 in Review
29 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Immunome (IMNM) for Q2 2021, worth a combined $41.1M — down 36% from $64.6M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of IMNM and 11 opened new positions — a net loss of 2 holders — while 7 trimmed existing stakes and 8 added.
The largest buyer was Prentice Capital Management, adding an estimated $4.09M. The largest seller was BlackRock, cutting an estimated $1.99M.
- 29 institutional investors held Immunome (IMNM) as of Q2 2021, down from 31 in Q1 2021.
- Funds reported $41.1M of Immunome stock for Q2 2021, down 36% quarter-over-quarter.
- 11 funds opened new Immunome positions in Q2 2021 and 13 closed out, a net change of -2 holders.
- The largest Immunome buyer in Q2 2021 was Prentice Capital Management, an estimated $4.09M added.
- The largest Immunome seller in Q2 2021 was BlackRock, an estimated $1.99M sold.
Based on aggregated 13F filings for Q2 2021.